JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI),...
Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™ manufacturing platform Masad Damha, PhD...
CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical...
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio...
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum...
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase...
Health Advance Partners Agree to Equity Stake in SingleTimeMicroneedles at a $3.5 Million ValuationSTORRS, CT / ACCESSWIRE / February 13,...
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI)...
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from...
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which...
CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer,...
Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing...
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune's...
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...